DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NOV 28 1983

NDA 88-481

Par Pharmaceutical, Inc.
Attention: Ashok Patel
12 Industrial Avenue
Upper Saddle River, NJ 07458

Gentlemen:

Reference is made to your abbreviated new drug application dated August 19, 1983, submitted pursuant to Section 505(b) of the Federal Food, Drug, and Cosmetic Act for Dexamethasone Tablets, 6.0 mg.

We acknowledge receipt of your correspondence of November 15, 1983, enclosing final printed labeling.

We have completed the review of this abbreviated new drug application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved.

Any significant change in the conditions outlined in this abbreviated new drug application requires an approved supplemental application before the change may be made, except for changes made in conformance with other provisions of Section 314.8 of the new drug regulations.

This Administration should be advised of any change in the marketing status of this drug.

For Initial Campaigns: We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your immediate advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Advertising and Labeling (HFN-240). Also, please do not use Form FD-2253 for this submission.

For Subsequent Campaigns: We call your attention to Regulation 21 CFR 310.300(b)(3) which requires that material for any subsequent advertising or promotional campaigns, at the time of their initial use, be submitted

to our Division of Drug Advertising and Labeling (HFN-240) with a completed Form FD-2253. A copy of Form FD-2253 is enclosed for your convenience.

The enclosures summarize the conditions relating to the approval of this application.

Sincerely yours,

Marvin Seife, M.D.
Director
Division of Generic Drugs
Office of Drug Standards
National Center for Drugs and Biologics

Enclosures:
Conditions of Approval of a New Drug Application
Records and Reports Requirements
Form LFD 2253